How we report the news.
How we choose stories, check them, and put things right when we get them wrong.
What we cover
Every day we report on published studies, clinical trials, approvals and regulator decisions in biotech and medicine, with a focus on peptides and on research coming out of China. Our illness pages follow one condition at a time, from how it was first treated to the trials running today.
Where the facts come from
Journals, trial registries, regulators, health charities and established news outlets. Every statement links to its source so you can read it for yourself.
If a number comes from the company that ran the trial, we say so. If a result comes from mice, or from 40 patients, we say that too, because the size and stage of a study matter as much as the headline.
Failures get the same space as successes
A trial that misses its goal, stalls or is stopped is reported as plainly as one that works. When a source explains why a programme ended, we give that reason. When nobody has said, we say that no reason has been published, and we don't guess.
What we don't do
We don't tell anyone what to take or buy, we don't rank treatments, and we don't call anything a cure. This is news and science history, not medical advice, and nothing here is a reason to start or stop a treatment without talking to your doctor.
Keeping pages current
Each illness page shows a "last checked" date. That is the day we last compared the page with its sources. When a trial reports or a regulator decides, we update the page.
Mistakes
If you spot something wrong, write to [email protected] and tell us where. We will check it against the source and fix it, and if the fix changes what a story says, we will note that on the page.
The news and the business
The illness pages carry no product links and no advertising. OrientSciences also runs a peptide research catalogue, and some daily stories link to the matching record.
Nothing on these pages is a recommendation to buy any product. This is purely the news side of our business.